Driven by evidence
Treat complex aneurysms withÌý
Contour Neurovascular Systemâ„¢
With 6 key clinical studies and counting, the Contour Neurovascular System is proven to be effective in the treatment of aneurysms.
"The findings demonstrate that the Contour Neurovascular System is a promising technology for the endovascular embolization of cerebral aneurysms.
With its high occlusion rates and safety profile, Contour could be considered a viable alternative to existing intrasaccular devices."
Contour Neurovascular System for endovascular embolization of cerebral aneurysms: a multicenter cohort study of 10 European neurovascular centers
___________
Method:
Retrospective review of utilizing prospectively collected cases from 10 European neurovascular centers, gathered between February 2017 and October 2022.
British Medical Journal (BMJ) | 2024
Christoph J Griessenauer | Sherief Ghozy | Alessandra Biondi | Constantin Hecker | Fritz Wodarg | Thomas Liebig | Tufail Patankar | Saleh Lamin | Mario MartÃnez-Galdámez | Christophe Cognard | Jens Fiehler | Franziska Dorn | Adam A Dmytriw | Monika Killer-Oberpfalzer
Results
Efficacy:
91.5%
91.5%
Adequate occlusion rate
At 6-12 month follow-up:
• Functional outcomes
- mRS 0 or 1 in 92.5%
Retreatment rate:
2.5%
2.5%
Retreatment rate
No association between rupture status or aneurysm size on occlusion rates or complications
Ease of use:
2.9%
2.9%
Change in size
Size simplified
•95.3% technical success
Safety:
0.4%
0.4%
HEM complication rate
•6.8% thromboembolic complications
•0.0% procedure-related mortality*
Overview
279 aneurysms
Median age 60 years, IQR 52-68 years
Aneurysm location
MCA 74 (26.5%)
ACOM 73 (26.2%)
Basilar tip 65 (23.3%)
ICA terminus/bifurcation 27 (9.7%)
ICA sidewall 15 (5.4%)
PCOM 16 (5.7%)
Other 9 (3.3%)
Median aneurysm size:
| Dome | 5.2mm (IQR 4.2-7.0) |
| Height | 5.7mm (IQR 4.3-7.8) |
| Neck | 3.9mm (IQR 3.0-5.0) |
- 83.2% elective, (16.8% ruptured) 11.1% acute SAH, 5.7% prior SAH.
- Reflects real-world usage, including atypical aneurysm locations (sidewall, non-bifurcation).
- Dual antiplatelets were given in 46.6% of aneurysms, monotherapy in 49.1%, and no antiplatelets were given in 4.3%.
We are driven by clinical evidence and committed to proving the safety and effectiveness of our products in treating the toughest stroke cases.
Contact us.
Thank you for your submission.
*There were four mortalities reported each at discharge and last follow-up, respectively, neither related to the Contour procedure.
This document is intended solely for the use of healthcare professionals.
A physician must always rely on his or her own professional clinical judgment when deciding whether to use a particular product when treating a particular patient. ŠÊ˜·³Ç does not dispense medical advice and recommends that physiciansÌý be trained in the use of any particular product before using it in a procedure. The information presented is intended to demonstrate the breadth of ŠÊ˜·³Ç product offerings. A physician must always refer to the package insert, product label and/or instructions for use before using any ŠÊ˜·³Ç product.
Products may not be available in all markets because product availability is subject to the regulatory and/or medical practices in individual markets. Please contact your ŠÊ˜·³Ç representative if you have questions about the availability of ŠÊ˜·³Ç products in your area.
ŠÊ˜·³Ç or its affiliated entities own, use, or have applied for the following trademarks or service marks: Contour Neurovascular System, ŠÊ˜·³Ç. All other trademarks are trademarks of their respective owners or holders.
The absence of a product, feature, or service name, or logo from this list does not constitute a waiver of ŠÊ˜·³Ç’s trademark or other intellectual property rights concerning that name or logo.
AP004642 v1.0